Kane Biotech Announces Amendment to its Credit Facility
WINNIPEG, Manitoba, March 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that it has entered into a formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”), to amend the terms of the Company’s amended and restated credit agreement between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”). The Company previously announced its intention to enter into the Amending Agreement on March 1, 2023.
- Not for distribution to U.S. news wire services or dissemination in the United States
WINNIPEG, Manitoba, March 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that it has entered into a formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”), to amend the terms of the Company’s amended and restated credit agreement between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”). - The Company previously announced its intention to enter into the Amending Agreement on March 1, 2023.
- The issuance of the Compensation Warrants is subject to the approval of the TSX Venture Exchange.
- “I would like to sincerely thank Pivot for their ongoing support of Kane especially as we approach some important inflection points in the Company.”